文献速递白血病造血干细胞移植与细胞治疗

适配器介导的CAR T细胞联合靶向急性髓系白血病的高效治疗

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
PubMed 文献 · Leukemia · 2024-09-18

本研究开发了靶向荧光素标记的AML抗原结合双体适配器的AdFITC-CAR T细胞平台,该平台可实现与AML抗原表达谱匹配的适配器组合使用及条件性活性调节。体外实验中适配器组合显著改善了对AML细胞的裂解;异种移植小鼠模型中,AdFITC-CAR T细胞联合单个双体适配器与直接CAR T细胞疗效相当,适配器组合使用进一步增强了对细胞系和原代AML的治疗效果。

要点

  • AdFITC-CAR T细胞平台可实现与AML抗原表达谱匹配的适配器选择和条件性活性调节。
  • 体外实验中适配器组合显著改善了对AML细胞的裂解。
  • 异种移植小鼠模型中适配器组合使用增强了对细胞系和原代AML的治疗效果。

核心结论

  • 本研究提供概念验证:AdFITC-CAR T细胞与适配器组合可有效增强对AML的免疫靶向。

研究设计与样本

  • 研究开发了靶向荧光素标记的AML抗原结合双体适配器的AdFITC-CAR T细胞,并在体外及治疗性异种移植小鼠模型中进行验证。

主要发现

  • 体外实验中,适配器组合显著改善了对AML细胞的裂解。
  • 治疗性异种移植小鼠模型中,AdFITC-CAR T细胞联合单个双体适配器与直接CAR T细胞疗效相当。
  • 治疗性异种移植小鼠模型中,适配器组合使用进一步增强了对细胞系和原代AML的治疗效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CAR T-cell products targeting lineage-specific cell-of-origin antigens, thereby eliminating both tumor and healthy counterpart cells, are currently clinically approved therapeutics in B- and plasma-cell malignancies. While they represent a major clinical improvement, they are still limited in terms of efficacy by e.g. single, sometimes low-expressed antigen targeting, and in terms of safety by e.g., lack of on-off activity. Successful cell-of-origin non-discriminative targeting of heterogeneous hematopoietic stem and progenitor cell malignancies, such as acute myeloid leukemia (AML), will require antigen-versatile targeting and off-switching of effectors in order to then allow rescue by hematopoietic stem cell transplantation (HSCT), preventing permanent myeloablation. To address this, we developed adaptor-CAR (AdFITC-CAR) T-cells targeting fluoresceinated AML antigen-binding diabody adaptors. This platform enables the use of adaptors matching the AML-antigen-expression profile and conditional activity modulation. Combining adaptors significantly improved lysis of AML cells in vitro. In therapeutic xenogeneic mouse models, AdFITC-CAR T-cells co-administered with single diabody adaptors were as efficient as direct CAR T-cells, and combinatorial use of adaptors further enhanced therapeutic efficacy against both, cell lines and primary AML. Collectively, this study provides proof-of-concept that AdFITC-CAR T-cells and combinations of adaptors can efficiently enhance immune-targeting of AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Volta L, Myburgh R, Pellegrino C, et al. Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia. 2024. PMID: 39294295. doi:10.1038/s41375-024-02409-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。